PD Dr. Felix Bock - Curriculum Vitae

Education and professional career

since 2018: DFG principal investigator (BO4489/1-3)
since 2017: Co-Principal Investigator, B3 “Novel therapeutic role of myeloid cell-derived VEGF-C and lymphangiogenesis in resolution of corneal inflammation and reestablishment of corneal transparency”, Center for Molecular Medicine Cologne (CMMC)
since 2017: Member of the Young Academics Committee/Faculty-Tenure Committee of the Medical Faculty of the University Cologne
2016: abilitation and obtaining the venia legendi for Experimental Ophthalmology
since 2015: DFG principal investigator (FOR 2240 TP1/BO4489/1-1)
since 2011: Laboratory Leader CorneaLab, Experimental Ophthalmology, Department of Ophthalmology, University of Cologne Director of the Readings Centre CORIC (Cologne Ophthalmological Reading and Image Analysis Center)
2009: IZKF-foreign exchange scholarship at Schepens Eye Research Institute, Harvard Medical School, Boston, MA, USA (Laboratory of Prof. Sharmila Masli)
2008-2011: DFG Postdoctoral fellow at Department of Ophthalmology, University of Erlangen (Laboratory of Prof. Claus Cursiefen)
2005-2008: PhD (summa cum laude) at the University of Erlangen
2002-2004: Study of Biology at the University of Saarland Diploma in Biology
2001-2002: Study of Biology at the University of Erlangen

Awards, distinctions and professional activities

2011: Sicca-Research Award 2011 DOG Ressort Dry Eye  
2010: Streilein Foundation Travel Grant
2009: Sicca-Research 2009 DOG Ressort Dry Eye  
2009: 2009 ARVO ISOCB Conference Travel Grant
2007: Young Investigator Publication Award IZKF Erlangen
2006: Travel Award of the ‘Tear Film and Ocular Surface Society’ (TFOS)

Selected publications

Hou Y, Le VNH, Clahsen T, Schneider AC, Bock F, Cursiefen C (2017). Photodynamic Therapy Leads to Time-Dependent Regression of Pathologic Corneal (Lymph) Angiogenesis and Promotes High-Risk Corneal Allograft Survival. Invest Ophthalmol Vis Sci. Nov 1;58(13):5862-5869.

Bock F, Onderka J, Braun G, Schneider A-S, Hos D, Bi Y, Bachmann B, Cursiefen C (2016).  Identification of novel endogenous anti(lymph)angiogenic factors in the aqueous humor. Invest Ophthalmol Vis Sci. Dec 1;57(15):6554-6560.
 
Bock F, Matthaei M, Reinhard T, Böhringer D, Christoph J, Ganslandt T, Cursiefen C (2014). High-dose subconjunctival cyclosporine a implants do not affect corneal neovascularization after high-risk keratoplasty. Ophthalmology. Sep;121(9):1677-82.
 
Lipp M, Bucher F, Parthasarathy A, Hos D, Onderka J, Cursiefen C, Bock F (2014). Blockade of the VEGF isoforms in inflammatory corneal hemangiogenesis and lymphangiogenesis. Graefes Arch Clin Exp Ophthalmol. Jun;252(6):943-9.

Bucher F, Parthasarathy A, Bergua A, Onderka J, Regenfuss B, Cursiefen C, Bock F (2014). Topical Ranibizumab inhibits inflammatory corneal hem- and lymphangiogenesis.  Acta Ophthalmol. Mar;92(2):143-8.

Bock F, Maruyama K, Regenfuss B, Hos D, Steven P, Heindl LM, Cursiefen C. (2013) Novel anti(lymph)angiogenic treatment strategies for corneal and ocular surface diseases. Prog Retin Eye Res. May;34:89-124.

Bucher F, Bi Y, Gehlsen U, Hos D, Cursiefen C, Bock F (2014). Regression of mature lymphatic vessels in the cornea by photodynamic therapy. Br J Ophthalmol. Mar;98(3):391-5.
 
Bock F, Rössner S, Onderka J, Lechmann M, Pallotta MT, Fallarino F, Boon L, Nicolette C, DeBenedette MA, Tcherepanova IY, Grohmann U, Steinkasserer A, Cursiefen C, Zinser E (2013) Topical application of soluble CD83 induces IDO-mediated immune modulation, increases Foxp3+ T cells, and prolongs allogeneic corneal graft survival. J Immunol. 191(4):1965-75.

Steven P*, Bock F*, Hüttmann G, Cursiefen C (2011). Intravital two-photon microscopy of immune cell dynamics in corneal lymphatic vessels. PLoS One.;6(10):e26253.

Dietrich T*, Bock F*, Yuen D, Hos D, Bachmann BO, Zahn G, Wiegand S, Chen L, Cursiefen C (2010) Cutting edge: lymphatic vessels, not blood vessels, primarily mediate immune rejections after transplantation. J Immunol 184(2):535-9 *contributed equally.